Body mass index (BMI) and outcome of metastatic melanoma patients receiving targeted therapy and immunotherapy: a multicenter international retrospective study.
Piotr Lukasz RutkowskiAlice IndiniMatilde De LucaBarbara MerelliAnna Mariuk-JaremaPawel TeteryczPawel RogalaIwona LugowskaBozena Cybulska-StopaAlice LabiancaLorenza Di GuardoMichele Del VecchioJacopo PigozzoGiovanni RandonFrancesca CortiCarlo Alberto TondiniEliana RulliMario MandalaPublished in: Journal for immunotherapy of cancer (2021)
In patients with metastatic melanoma receiving ICIs, there is no impact of BMI on DCR, PFS and OS. The late prognostic effect of BMI in patients treated with MAPKi should be considered hypothesis generating and needs to be further investigated.